JPWO2022120144A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022120144A5 JPWO2022120144A5 JP2023533928A JP2023533928A JPWO2022120144A5 JP WO2022120144 A5 JPWO2022120144 A5 JP WO2022120144A5 JP 2023533928 A JP2023533928 A JP 2023533928A JP 2023533928 A JP2023533928 A JP 2023533928A JP WO2022120144 A5 JPWO2022120144 A5 JP WO2022120144A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- composition
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121194P | 2020-12-03 | 2020-12-03 | |
| US63/121,194 | 2020-12-03 | ||
| PCT/US2021/061764 WO2022120144A1 (en) | 2020-12-03 | 2021-12-03 | Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024501430A JP2024501430A (ja) | 2024-01-12 |
| JP2024501430A5 JP2024501430A5 (https=) | 2024-12-09 |
| JPWO2022120144A5 true JPWO2022120144A5 (https=) | 2024-12-09 |
Family
ID=79024222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533928A Pending JP2024501430A (ja) | 2020-12-03 | 2021-12-03 | 皮膚エリテマトーデス及び全身性エリテマトーデスの治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240018246A1 (https=) |
| EP (1) | EP4255392A1 (https=) |
| JP (1) | JP2024501430A (https=) |
| KR (1) | KR20230119664A (https=) |
| CN (1) | CN116963716A (https=) |
| AR (1) | AR124247A1 (https=) |
| AU (1) | AU2021391803A1 (https=) |
| CA (1) | CA3203971A1 (https=) |
| CL (1) | CL2023001562A1 (https=) |
| CO (1) | CO2023008272A2 (https=) |
| IL (1) | IL303279A (https=) |
| MX (1) | MX2023006474A (https=) |
| PE (1) | PE20231678A1 (https=) |
| TW (1) | TW202222829A (https=) |
| WO (1) | WO2022120144A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118638234B (zh) * | 2024-07-04 | 2025-10-14 | 杭州博之锐生物制药有限公司 | 抗bdca2抗体及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU785198B2 (en) * | 1999-11-15 | 2006-11-02 | Miltenyi Biotec B.V. & Co. KG | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognised thereby and cells obtained thereby |
| CN111961134B (zh) * | 2012-12-10 | 2024-04-05 | 比奥根Ma公司 | 抗血液树突细胞抗原2抗体及其用途 |
| US10294301B2 (en) * | 2013-12-24 | 2019-05-21 | Astellas Pharma Inc. | Anti-human BDCA-2 antibody |
| MA44763A (fr) | 2016-04-28 | 2019-03-06 | Biogen Ma Inc | Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang |
-
2021
- 2021-12-03 CA CA3203971A patent/CA3203971A1/en active Pending
- 2021-12-03 AU AU2021391803A patent/AU2021391803A1/en active Pending
- 2021-12-03 AR ARP210103370A patent/AR124247A1/es unknown
- 2021-12-03 EP EP21827347.2A patent/EP4255392A1/en active Pending
- 2021-12-03 MX MX2023006474A patent/MX2023006474A/es unknown
- 2021-12-03 TW TW110145254A patent/TW202222829A/zh unknown
- 2021-12-03 IL IL303279A patent/IL303279A/en unknown
- 2021-12-03 KR KR1020237022397A patent/KR20230119664A/ko active Pending
- 2021-12-03 WO PCT/US2021/061764 patent/WO2022120144A1/en not_active Ceased
- 2021-12-03 US US18/038,911 patent/US20240018246A1/en active Pending
- 2021-12-03 JP JP2023533928A patent/JP2024501430A/ja active Pending
- 2021-12-03 PE PE2023001760A patent/PE20231678A1/es unknown
- 2021-12-03 CN CN202180091232.0A patent/CN116963716A/zh active Pending
-
2023
- 2023-05-31 CL CL2023001562A patent/CL2023001562A1/es unknown
- 2023-06-23 CO CONC2023/0008272A patent/CO2023008272A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7080263B2 (ja) | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 | |
| US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| US20230159628A1 (en) | Anti-CGRP Antibody Formulation | |
| JP2025172841A5 (https=) | ||
| JP2023139290A (ja) | 安定的抗ｏｓｍｒ抗体製剤 | |
| WO2023011502A1 (zh) | 含有抗il-4r抗体的稳定制剂 | |
| US20210324052A1 (en) | Formulations of anti-rsv antibodies and methods of use thereof | |
| KR20220082000A (ko) | 후천성 혈우병 a의 예방 및/또는 치료에 이용되는 의약 조성물, 및 당해 의약 조성물을 포함하는 제품 | |
| JPWO2022120144A5 (https=) | ||
| US20240175027A1 (en) | Anti-c5 antibody/c5 irna co-formulations and combination therapies | |
| CN118056572A (zh) | 含有抗il-17抗体的稳定制剂 | |
| JP2025513510A (ja) | オクレリズマブを含む薬学的組成物とその用途 | |
| CA3115708C (en) | Formulations of anti-rsv antibodies and methods of use thereof | |
| WO2022234439A1 (en) | Treatment for systemic lupus erythematosus using anti-baffr antibodies | |
| HK40115478A (zh) | 抗cd22抗体的水性制剂及其用途 | |
| JPWO2021257947A5 (https=) | ||
| OA17126A (en) | Pharmaceutical formulations of TNF-alpha antibodies | |
| JP2020517636A (ja) | 慢性炎症性脱髄性多発神経炎の治療における使用のための免疫グロブリン製品 | |
| JPWO2022206938A5 (https=) |